Already in the tissues of the eye is transformed into dipivefrin
adrenaline and has hypotensive action, folding of
three factors: the improvement of the outflow of fluid in the drainage system, stimulation
uveoscleral outflow path, a small and short-term depression
production of intraocular fluid. However, compared with instillation
epinephrine side effects are expressed to a much lesser degree.
Since only 3% of patients from those who had to stop
instillation of adrenalin due to intolerance to the dasg, not
could use dipivefrin. Using the "prodasg" reduces
dose due to increased absorption and the hypotensive effect of 0.1%
dipivefrina solution corresponds to the effect of 2% solution of adrenaline.
After a single instillation of onset of action is noted
30 minutes later, the maximum expression of an hour. Usual dose
is the burying of 0.1% solution twice a day. Percentage reduction
intraocular pressure (IOP) in patients with primary open
glaucoma, on average 20-24% of the baseline. Dipivefrin can
be added to the basic treatment by other means to enhance
hypotensive effect.
Dipivefrin hydrochloride not be prescribed to patients
with narrow anterior chamber angle, as mydriasis can cause
rise in IOP. May develop swelling of the retina in the macular region
(This is especially tase for patients with aphakia), which is fully
docked after dasg withdrawal. Rarely seen dark pigmentation
edges of eyelids and anterior eye, no effect on organ function
view. Systemic side effects characteristic of adrenaline (tachycardia,
increased blood pressure, pain in the heart, etc.) are rare.